4 results about "Activation lymphocyte" patented technology

Disclosed herein is a composition for enhancing an abscopal effect of radiation, including a lymphocyte activation gene-3 (LAG-3) inhibitor and a programmed cell death protein-1 (PD-1) inhibitor. One aspect relates to a method of enhancing an abscopal effect of radiation by co-administering a composition including an LAG-3 inhibitor and a PD-1 inhibitor in conjunction with radiotherapy in the treatment of cancer (e.g., triple-negative breast cancer).

A assay for screening or determining the activity of a lymphocyte-activation gene 3 (LAG-3) agonist is described. According to the assay, a plurality of effector T cells is provided, each effector T cell expressing LAG-3 and a T cell receptor (TCR) on its surface and comprising a reporter gene encoding a reporter protein, wherein expression of the reporter protein is regulated by LAG-3-mediated inhibition of TCR signaling within the effector T cell. The activity of the agonist is determined according to the extent to which expression of the reporter protein is altered in the presence of the agonist as compared to expression of the reporter protein in the absence of the agonist. The assay can be used to determine the potency of a preparation of the agonist, as a quality control step in the production of the agonist, or for stability testing of a preparation of the agonist. A kit for performing the assay is also described.

The present application provides a method of treating cancer in a subject involving administering to the subject a bone marrow cell activator or therapy (e.g., a TLR agonist or STING agonist) and a TNF [alpha] inhibitor. In some cases, the methods further involve administering to the subject an SHP-1 inhibitor and / or a tyrosine kinase inhibitor, optionally further administering a lymphocyte activator (e.g., a cytokine (e.g., IL-2)) and / or an immune checkpoint inhibitor (e.g., anti-PD-1).

The disclosure provides a method of treating unresectable or metastatic melanoma in a human patient with a lymphocyte activation gene-3 (LAG-3) antagonist. In some aspects, the method includes a combination of the LAG-3 antagonist with a cytotoxic T-lymphocyte antigen-4 (CTLA-4) inhibitor. In some aspects, the method includes one or more additional therapeutic agents and / or anti-cancer therapies.